Dallas, TX: ReportsandReports announce it will carry Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile Market Research Report in its Store. Browse complete Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile Report Introduction This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Reasons to Purchase Table of Content ABOUT DATAMONITOR HEALTHCARE About the PharmaVitae team Chapter 1 About this profile PharmaVitae Explorer database Chapter structure Executive summary Quarterly news update Company introduction Company sales Company financials Key products and competitors Data sourcing Sales data Analyst consensus Chapter 2 Executive summary Key findings Financial performance, 2002-14 Takeda: PharmaVitae forecasts at a glance Strategic insight Prospect of blockbuster genericization prompts wave of pipeline investment Over 80% of current ethical sales will soon be exposed to generic competition Additional challenge set to arise from reforms to Japan healthcare system Capitalization helps to steer long-term strategy and innovation Follow-on therapies vital in limiting impact of generic penetration Takeda looks to Kapidex in order to maintain GERD presence Alogliptin launch delayed after FDA requests additional safety trial data SWOT analysis Strengths Weaknesses Opportunities Threats Table of Contents Table of figures Chapter 3 Quarterly news update Latest prescription pharma product news Q1 2010 Latest corporate news Q1 2010 Future product milestones Chapter 4 Company introduction Key findings Background Key corporate developments Out-licensing and TAP joint venture provide initial framework for US penetration Japanese healthcare reforms heighten competition in domestic market Consumer health Joint ventures M&A history Acquisition of Millennium Pharmaceuticals Acquisition of Paradigm Therapeutics Acquisition of Syrrx M&A strategy Chapter 5 Company sales Key findings Prescription pharmaceutical sales and growth rate analysis, 2002-14 Product analysis Product analysis, 2002-08 Product analysis, 2008-14 Growth drivers Growth resistors Therapy area analysis Geographic analysis Launch/core/expiry analysis Explanation of launch/core/expiry analysis Launch analysis, 2008-14 Core analysis, 2008-14 Expiry analysis, 2008-14 Launch/core/expiry configuration, 2008-14 Molecule type analysis Externalization analysis Chapter 6 Company financials Key findings Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 Operating costs and profit analysis Operating costs and profit analysis, 2002-08 Operating cost ratio and profit margin analysis, 2002-08 Operating cost ratio and profit margin analysis, 2008-14 Operating costs and profit analysis, 2008-14 Chapter 7 Key products and competitors Key findings Overview Gastroenterology Kapidex Overview Sales forecast Takeda goes it alone with Prevacid follow-on Major competitive threat from generics Takepron/Prevacid Overview Sales forecast Second-generation PPI sees considerable sales under TAP alliance OTC Prevacid set to launch following US patent expiry Prevacid sales slow as uptake of generic omeprazole continues to rise US exclusivity lost following November 2009 patent expiry Amitiza Overview Sales forecast New bowel disorder therapy launched in 2006 under license from Sucampo Impressive early uptake in the US driven by strong clinical evidence Indication broadening set to enhance venture further Cardiovascular Blopress/Blopress Comp Overview Sales forecast Blockbuster ARB franchise with Japanese patent extension out to 2016 Antihypertensive market overview Genericization of ARB class will erode Blopress market share Endocrine, metabolic and genetic disorders Actos/ACTOplus Met Overview Sales forecast Blockbuster antidiabetic gains market-leading status after demise of competitor Overview of TZD therapeutic use Further new launches in place to help safeguard against generic Actos Further growth in Actos franchise sales expected out to patent expiry Alogliptin franchise Overview Sales forecast SYR-322 is seen as Takeda’s long-term replacement for Actos in the diabetes market Alogliptin approval delayed by lack of data pertaining to cardiovascular risks Type 2 diabetes market potential set for further expansion Actos/alogliptin combination should add significant value to diabetes franchise Oncology Lupron Depot Overview Sales forecast LHRH agonist gives Takeda market-leading presence in hormonal therapeutic intervention Reformulations help Takeda build successful defense against generic leuprolide Velcade Overview Sales forecast Acquisition of Millennium equips Takeda with enhanced oncology focus Velcade is the market-leading treatment for relapsed or refractory multiple myeloma Label extension boosts uptake following initial approval in third-line setting Velcade in direct competition with Revlimid Immunology & inflammation Enbrel Overview Sales forecast Takeda’s biologic presence boosted by Japanese rights to gold standard TNF inhibitor Chapter 8 Appendix R&D pipeline References Abbreviations Exchange rates About Datamonitor About Datamonitor Healthcare Datamonitor consulting Disclaimer Browse complete Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile Report Browse all Healthcare Market Research Reports Browse all Datamonitor Market Research Reports RSS Browse all Latest Report Related Reports: Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile Daiichi Sankyo Co., Ltd: PharmaVitae Profile Eisai Co. Ltd: PharmaVitae Profile About Us: Contact:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
Posted by
Unknown
on
